Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devan V Mehrotra

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
AIDS Research and Human Retroviruses|February 1, 2007
Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMCLisa S Kierstead, Sheri Dubey, Barbara Meyer, et al.
Vaccine|October 13, 2010
Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humansAndrew J Bett, Sheri A Dubey, Devan V Mehrotra, et al.
Lancet (London, England)|November 18, 2008
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialSusan P Buchbinder, Devan V Mehrotra, Ann Duerr, et al.
The Journal of Infectious Diseases|November 26, 2009
Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimensDavid M Asmuth, Elizabeth L Brown, Mark J DiNubile, et al.
Lancet (London, England)|November 18, 2008
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysisM Juliana McElrath, Stephen C De Rosa, Zoe Moodie, et al.
Clinical Trials (London, England)|October 23, 2009
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting teamBrenda J Crowe, H Amy Xia, Jesse A Berlin, et al.
Journal of Cardiac Failure|August 30, 2025
Assessing Benefit in Heart Failure Patients with Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk StratificationChristopher M O'Connor, Sarah Rathwell, Devan V Mehrotra, et al.
AIDS Research and Human Retroviruses|December 26, 2008
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adultsClayton D Harro, Michael N Robertson, Michelle A Lally, et al.
AIDS Research and Human Retroviruses|September 22, 2010
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy AdultsOuzama Nicholson, Fay DiCandilo, James Kublin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 25, 2008
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adultsFrances H Priddy, Deborah Brown, James Kublin, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
AIDS Research and Human Retroviruses|February 1, 2007
Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMCLisa S Kierstead, Sheri Dubey, Barbara Meyer, et al.
Vaccine|October 13, 2010
Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humansAndrew J Bett, Sheri A Dubey, Devan V Mehrotra, et al.
Lancet (London, England)|November 18, 2008
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialSusan P Buchbinder, Devan V Mehrotra, Ann Duerr, et al.
The Journal of Infectious Diseases|November 26, 2009
Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimensDavid M Asmuth, Elizabeth L Brown, Mark J DiNubile, et al.
Lancet (London, England)|November 18, 2008
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysisM Juliana McElrath, Stephen C De Rosa, Zoe Moodie, et al.
Clinical Trials (London, England)|October 23, 2009
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting teamBrenda J Crowe, H Amy Xia, Jesse A Berlin, et al.
Journal of Cardiac Failure|August 30, 2025
Assessing Benefit in Heart Failure Patients with Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk StratificationChristopher M O'Connor, Sarah Rathwell, Devan V Mehrotra, et al.
AIDS Research and Human Retroviruses|December 26, 2008
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adultsClayton D Harro, Michael N Robertson, Michelle A Lally, et al.
AIDS Research and Human Retroviruses|September 22, 2010
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy AdultsOuzama Nicholson, Fay DiCandilo, James Kublin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 25, 2008
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adultsFrances H Priddy, Deborah Brown, James Kublin, et al.
Pageof 8